Caplight Directory>Companies>Accure Therapeutics-preview>Accure-health


Accure Therapeutics

Private
BarcelonaHealthcare & Life Sciences

Last Round

Grant

Apr 7, 2025

Total Funding Raised

$9.7M

Momentum Score

25 /100

Company Overview

Accure Therapeutics is a biotechnology company that develops a portfolio of new drug candidates to treat Central Nervous System (CNS) diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

CNS therapeuticsdisease-modifying therapydrug licensingneuroprotectionclinical-stage biotechneurorepairpharma R&Dcentral nervous systemCNSasset-centric biotechpharma partnershipsParkinson's diseaseoptic neuritisfirst-in-class drugsPREP inhibitordrug discoverytranslational R&Depilepsy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Accure Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Accure Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantApr 7, 2025
Series AMay 26, 2020
View all Funding Rounds

Key People

Founding team and executive leadership

Paul Bikard

Chief Financial Officer

Executive Team

Accure Therapeutics Investors

Notable investors and investment history

InvestorRounds
Alta Life SciencesSeries A
Luxembourg National Research FundGrant
The Michael J. Fox Foundation for Parkinson's ResearchGrant
University of BarcelonaGrant, Series A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Monthly visitors grew 44% MoM.

  • Apr 7, 2025

    $1.6M grant received

View all signals

Accure Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Accure Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Accure Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range12
Year Founded2020
Last FundingApr 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.